Pub Date : 2023-06-30DOI: 10.18549/pharmpract.2023.2.2776
Beatrice Hawila, Diana Malaeb, S. Hallit, S. Obeid
{"title":"Association between Covid-19 vaccination, fear of COVID-19 and female sexual satisfaction among a sample of Lebanese women: A pilot study","authors":"Beatrice Hawila, Diana Malaeb, S. Hallit, S. Obeid","doi":"10.18549/pharmpract.2023.2.2776","DOIUrl":"https://doi.org/10.18549/pharmpract.2023.2.2776","url":null,"abstract":"","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"1 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90142829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.18549/pharmpract.2023.2.2823
Yopi Rikmasari, T. Andayani, S. A. Kristina, D. Endarti
Background: Poor self-management has been associated with uncontrolled blood pressure in hypertensive patients. A valid instrument is needed to assess the self-management of hypertensive patients, especially to measure self-management changes after health workers’ intervention. Objective: To examine the psychometric properties Persian Hypertension Self-Management Questionnaire among patients with hypertension in Indonesia. Methods: Data collection was carried out cross-sectionally using convenience sampling; obtained 407 hypertensive patients in ten primary health centers in South Sumatra Province. The translation of the questionnaire has been carried out by applying forward-backward methods. The Face validity test based on respondents’ responses to each question item was evaluated descriptively. We evaluated content validity by an expert with qualitative and quantitative; known group validity was analyzed using chi-square. Internal consistency reliability test using Cronbach alpha and test-retest reliability using Pearson correlation test or Pearson Spearman rank correlation. Results: Content validity by the expert shows sentence improvement, and CVI value = 1.00. Face validity shows that respondents can understand well to the questionnaire, and the known group validity was considered very good, as indicated by a significant relationship between the level of self-management and blood pressure control (p <0.001). The reliability assessment on internal consistency was 0.823 with a range of values for each domain, namely 0.710 - 0.823, and Test-retest reliability of 0.707 (p <0.001) with values ranging from 0.600 - 0.906. Conclusions: The Persian Hypertension Self-Management Questionnaire has been translated into the Indonesian version and has satisfactory validity and reliability for assessing self-management in hypertensive patients in Indonesia.
{"title":"Translation, cultural adaptation, and psychometric validation of the Persian hypertension self-management questionnaire in South Sumatera, Indonesia","authors":"Yopi Rikmasari, T. Andayani, S. A. Kristina, D. Endarti","doi":"10.18549/pharmpract.2023.2.2823","DOIUrl":"https://doi.org/10.18549/pharmpract.2023.2.2823","url":null,"abstract":"Background: Poor self-management has been associated with uncontrolled blood pressure in hypertensive patients. A valid instrument is needed to assess the self-management of hypertensive patients, especially to measure self-management changes after health workers’ intervention. Objective: To examine the psychometric properties Persian Hypertension Self-Management Questionnaire among patients with hypertension in Indonesia. Methods: Data collection was carried out cross-sectionally using convenience sampling; obtained 407 hypertensive patients in ten primary health centers in South Sumatra Province. The translation of the questionnaire has been carried out by applying forward-backward methods. The Face validity test based on respondents’ responses to each question item was evaluated descriptively. We evaluated content validity by an expert with qualitative and quantitative; known group validity was analyzed using chi-square. Internal consistency reliability test using Cronbach alpha and test-retest reliability using Pearson correlation test or Pearson Spearman rank correlation. Results: Content validity by the expert shows sentence improvement, and CVI value = 1.00. Face validity shows that respondents can understand well to the questionnaire, and the known group validity was considered very good, as indicated by a significant relationship between the level of self-management and blood pressure control (p <0.001). The reliability assessment on internal consistency was 0.823 with a range of values for each domain, namely 0.710 - 0.823, and Test-retest reliability of 0.707 (p <0.001) with values ranging from 0.600 - 0.906. Conclusions: The Persian Hypertension Self-Management Questionnaire has been translated into the Indonesian version and has satisfactory validity and reliability for assessing self-management in hypertensive patients in Indonesia.","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"17 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81759651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.18549/pharmpract.2023.2.2804
Fatima Mohamed Alzaabi, S. Beshir, Emad Abdel Fattah, S. Gillani
Objective: This study evaluated the effectiveness of Evolocumab by measuring achievement target LDL-C among high-risk ASCVD patients in the UAE. Method: A retrospective observational study included 27 patients with high-risk ASCVD receiving Evolocumab 140 mg/mL SC injection every 2 weeks. The effectiveness of Evolocumab is measured by the mean reduction in LDL-C levels from baseline and achieving target LDL levels according to ECS/EAS guideline during average follow up period. Results: The average (SD) age of the patients is 52 (10) years. Majority of the patients were male (n=22), smokers (40.9%), overweight or obese (78%), had a history of hypertension (59.3%), MI (55.5%) and diabetes (40.7%). The patients were on Evolucomab therapy due to persistently elevated LDL-C (n=25) or statin intolerance (n=2). During the average follow up period of 42 weeks,14 patients (51%) achieved target LDL-C level. During this period, LDL-C and TC levels reduced from 3.51(1.3) mmol/L to 1.9 (1.2) mmol/L and from 4.97 (1.4) mmol/L to 1.62 (1.09) mmol/L, respectively post Evolocumab therapy. Conclusion: The reduction was statistically significant. However, the reduction of TG levels and the increase in HDL level was not significant. Evolocumab reduces LDL-C and TC levels significantly in high-risk ASCVD patients in a tertiary hospital in the UAE population.
{"title":"Retrospective study on clinical efficacy of Evolocumab in highrisk ASCVD patients","authors":"Fatima Mohamed Alzaabi, S. Beshir, Emad Abdel Fattah, S. Gillani","doi":"10.18549/pharmpract.2023.2.2804","DOIUrl":"https://doi.org/10.18549/pharmpract.2023.2.2804","url":null,"abstract":"Objective: This study evaluated the effectiveness of Evolocumab by measuring achievement target LDL-C among high-risk ASCVD patients in the UAE. Method: A retrospective observational study included 27 patients with high-risk ASCVD receiving Evolocumab 140 mg/mL SC injection every 2 weeks. The effectiveness of Evolocumab is measured by the mean reduction in LDL-C levels from baseline and achieving target LDL levels according to ECS/EAS guideline during average follow up period. Results: The average (SD) age of the patients is 52 (10) years. Majority of the patients were male (n=22), smokers (40.9%), overweight or obese (78%), had a history of hypertension (59.3%), MI (55.5%) and diabetes (40.7%). The patients were on Evolucomab therapy due to persistently elevated LDL-C (n=25) or statin intolerance (n=2). During the average follow up period of 42 weeks,14 patients (51%) achieved target LDL-C level. During this period, LDL-C and TC levels reduced from 3.51(1.3) mmol/L to 1.9 (1.2) mmol/L and from 4.97 (1.4) mmol/L to 1.62 (1.09) mmol/L, respectively post Evolocumab therapy. Conclusion: The reduction was statistically significant. However, the reduction of TG levels and the increase in HDL level was not significant. Evolocumab reduces LDL-C and TC levels significantly in high-risk ASCVD patients in a tertiary hospital in the UAE population.","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"59 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78164942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.18549/pharmpract.2023.2.2811
Israa Y El-Khidir, Asim Ahmed Elnour, Abdulla Al Amoodi, Abrar Ayad Alrashdi, Haifa Hamoud Almansour, Teif Abdulkarim Almarwani, S. Alrwili, Shahad Fayad Alrowaili, Shouq Lutfi Al Khudhairy, Asma Faisal Alshammari, A. Sadeq, Nadia Al Mazrouei, K. A. Al-Kubaisi, Hala Yousif EL Khidir, Maisoun Alkaabi, A. Ashoor
Background: Recently, direct oral anticoagulant (DOAC) has been projected for secondary prevention of recurrent ischemic events post-acute coronary syndrome (ACS). The addition of a DOAC to the antiplatelet regimen of subjects with the ACS is clinically practiced in candidates where compelling anticoagulation is indicated by high thromboembolic risk. The current evidence provides approved compelling indication for the DOAC, particularly for rivaroxaban which bears the strongest existing evidence. Objective: We intend to assess the role of DOAC in addition to single or dual antiplatelet therapy in subjects with ACS. We will compare the clinical characteristics and explore the efficacy and safety of the DOAC class members (apixaban, betrixaban, dabigatran, edoxaban and rivaroxaban) in terms of reduction in ischemic events in subjects with ACS (ST-segment elevation myocardial infarction [STEMI] or non–ST-segment elevation [NSTEMI]) or subjects who underwent percutaneous coronary intervention (PCI) and or ACS and coexisting atrial fibrillation (AF). Methods: Relevant data will be searched on known data-bases such as Embase, Google Scholar, the Cochrane Central, and PubMed. The trials included will be randomized controlled trials from 2009 to 2022. Subjects will be receiving DOAC for ACS were evaluated for inclusion. The extraction, synthesis, quality, and validity of data will follow the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The risk of bias tool, version 2.0 (Cochrane) will be used for risk of bias assessment. Data will be pooled using random-effects models. The primary outcome measure will be efficacy end point (composite of cardiovascular death, myocardial infarction, and stroke), while the safety outcome will be minor/major bleeding. Results: We will report the primary efficacy end point risk in the various regimens (DOAC plus SAPT or DAPT) with odds ratio (confidence interval) and both statistical and clinical significance. Further results of risk of bleeding will be compared between the regimens in the subsets of subjects with ACS (e.g. STEMI or NSTEMI) or with comorbid AF or heart failure (HF). Conclusion: We will critically appraise the evidence to support the effects of DOAC plus SAPT or DAPT based on the clinical presentation of subjects. The risk-benefit profile of DOAC will be presented in the two regimens of dual antithrombotic or triple antithrombotic therapy.
{"title":"Protocol for systematic review and meta-analysis on randomized clinical trials for direct oral anticoagulant in subjects with acute coronary syndrome","authors":"Israa Y El-Khidir, Asim Ahmed Elnour, Abdulla Al Amoodi, Abrar Ayad Alrashdi, Haifa Hamoud Almansour, Teif Abdulkarim Almarwani, S. Alrwili, Shahad Fayad Alrowaili, Shouq Lutfi Al Khudhairy, Asma Faisal Alshammari, A. Sadeq, Nadia Al Mazrouei, K. A. Al-Kubaisi, Hala Yousif EL Khidir, Maisoun Alkaabi, A. Ashoor","doi":"10.18549/pharmpract.2023.2.2811","DOIUrl":"https://doi.org/10.18549/pharmpract.2023.2.2811","url":null,"abstract":"Background: Recently, direct oral anticoagulant (DOAC) has been projected for secondary prevention of recurrent ischemic events post-acute coronary syndrome (ACS). The addition of a DOAC to the antiplatelet regimen of subjects with the ACS is clinically practiced in candidates where compelling anticoagulation is indicated by high thromboembolic risk. The current evidence provides approved compelling indication for the DOAC, particularly for rivaroxaban which bears the strongest existing evidence. Objective: We intend to assess the role of DOAC in addition to single or dual antiplatelet therapy in subjects with ACS. We will compare the clinical characteristics and explore the efficacy and safety of the DOAC class members (apixaban, betrixaban, dabigatran, edoxaban and rivaroxaban) in terms of reduction in ischemic events in subjects with ACS (ST-segment elevation myocardial infarction [STEMI] or non–ST-segment elevation [NSTEMI]) or subjects who underwent percutaneous coronary intervention (PCI) and or ACS and coexisting atrial fibrillation (AF). Methods: Relevant data will be searched on known data-bases such as Embase, Google Scholar, the Cochrane Central, and PubMed. The trials included will be randomized controlled trials from 2009 to 2022. Subjects will be receiving DOAC for ACS were evaluated for inclusion. The extraction, synthesis, quality, and validity of data will follow the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The risk of bias tool, version 2.0 (Cochrane) will be used for risk of bias assessment. Data will be pooled using random-effects models. The primary outcome measure will be efficacy end point (composite of cardiovascular death, myocardial infarction, and stroke), while the safety outcome will be minor/major bleeding. Results: We will report the primary efficacy end point risk in the various regimens (DOAC plus SAPT or DAPT) with odds ratio (confidence interval) and both statistical and clinical significance. Further results of risk of bleeding will be compared between the regimens in the subsets of subjects with ACS (e.g. STEMI or NSTEMI) or with comorbid AF or heart failure (HF). Conclusion: We will critically appraise the evidence to support the effects of DOAC plus SAPT or DAPT based on the clinical presentation of subjects. The risk-benefit profile of DOAC will be presented in the two regimens of dual antithrombotic or triple antithrombotic therapy.","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"24 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78573719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.18549/pharmpract.2023.2.2816
R. D. Castelino, K. Al Hashmi, M. Al Za’abi, Aly Abdelrahman
Background: Antiarrhythmic drugs are commonly used to treat arrhythmia. However, data on the usage pattern of antiarrhythmic drugs, associated side effects, and the role of clinical pharmacist interventions in the Middle East are scarce. Objective: The purpose of this study was to describe the usage pattern, side effects, and clinical pharmacist interventions of antiarrhythmic drugs at the Sultan Qaboos University Hospital (SQUH), a tertiary care hospital in Oman. Methods: This retrospective observational study included adult patients (≥18 years) who received at least one dose of antiarrhythmic drugs at SQUH between January 2020 and December 2021. Ethical approval was obtained prior to conducting the study. Results: In total, 400 patients were enrolled in this study. Their mean age was 62.5 ± 16.6 years (range:19-96), and 55.3% (221/400) were male. Atrial arrhythmias were the most commonly observed (344/400, 86.0%). Beta-blockers (337/500, 67.4%) were the most prescribed class of drugs. The most commonly prescribed drugs were bisoprolol (263/400, 65.8%), carvedilol (65/400, 16.3%), and amiodarone (59/400, 14.8%). The majority of patients (300/400, 75.0%) received monotherapy, whereas 25% (100/400) received combination therapy. A total of 109 side effects were reported in 45 patients, resulting in an incidence rate of 11.3 %, with cardiovascular side effects accounting for the majority (41/109, 37.6%) of these. Amiodarone had the highest prevalence of adverse effects (33/109, 30.3%). A total of 122 clinical pharmacist interventions were observed in 13.0 % (52/400) of patients. Beta-blockers were associated with more than half of the interventions (61/122, 50.0%). Age (61.84 years vs. 66.75 years; p=0.047), comorbidities (83.6% vs. 96.2%; p=0.019), renal impairment (19.6% vs. 40.4%; p=0.001, heart failure (11.8% vs. 28.9%; p=0.002), concomitant medications (84.5% vs. 98.1%; p=0.004), polypharmacy (51.1% vs. 69.2%; p=0.022) and duration of therapy of less than one year (9.3% vs. 27.3%; p<0.001) was significantly associated with the need for intervention. Conclusion: Beta-blockers were the most commonly prescribed antiarrhythmic drugs in SQUH. Amiodarone was associated with the highest prevalence of side effects. Clinical pharmacy intervention at the SQUH was mainly related to antiarrhythmic drug selection and dose optimization.
背景:抗心律失常药物是治疗心律失常的常用药物。然而，关于中东地区抗心律失常药物的使用模式、相关副作用和临床药师干预作用的数据很少。目的:本研究的目的是描述阿曼苏丹卡布斯大学医院(SQUH)抗心律失常药物的使用模式、副作用和临床药师干预措施。方法:这项回顾性观察性研究纳入了2020年1月至2021年12月期间在SQUH接受至少一剂抗心律失常药物治疗的成年患者(≥18岁)。在进行研究之前获得了伦理批准。结果:本研究共纳入400例患者。平均年龄62.5±16.6岁(范围:19 ~ 96岁)，男性占55.3%(221/400)。房性心律失常最常见(344/400,86.0%)。-受体阻滞剂(337/500,67.4%)是处方最多的一类药物。最常用的处方药物为比索洛尔(263/400,65.8%)、卡维地洛尔(65/400,16.3%)和胺碘酮(59/400,14.8%)。大多数患者(300/400,75.0%)接受单一治疗，而25%(100/400)接受联合治疗。45例患者共报告109种不良反应，发生率为11.3%，其中心血管不良反应占多数(41/109,37.6%)。胺碘酮不良反应发生率最高(33/109,30.3%)。临床药师干预122次，占13.0%(52/400)。β受体阻滞剂与半数以上的干预措施相关(61/122,50.0%)。年龄(61.84岁vs 66.75岁;P =0.047)，合并症(83.6% vs. 96.2%;P =0.019)，肾功能损害(19.6% vs. 40.4%;P =0.001，心力衰竭(11.8% vs. 28.9%;P =0.002)，合并用药(84.5% vs. 98.1%;P =0.004)，多药(51.1% vs. 69.2%;P =0.022)，治疗时间小于1年(9.3% vs. 27.3%;P <0.001)与干预需求显著相关。结论:受体阻滞剂是SQUH患者最常用的抗心律失常药物。胺碘酮的副作用发生率最高。医院的临床药学干预主要与抗心律失常药物的选择和剂量优化有关。
{"title":"Overview of the use of antiarrhythmic drugs at a tertiary hospital in Oman","authors":"R. D. Castelino, K. Al Hashmi, M. Al Za’abi, Aly Abdelrahman","doi":"10.18549/pharmpract.2023.2.2816","DOIUrl":"https://doi.org/10.18549/pharmpract.2023.2.2816","url":null,"abstract":"Background: Antiarrhythmic drugs are commonly used to treat arrhythmia. However, data on the usage pattern of antiarrhythmic drugs, associated side effects, and the role of clinical pharmacist interventions in the Middle East are scarce. Objective: The purpose of this study was to describe the usage pattern, side effects, and clinical pharmacist interventions of antiarrhythmic drugs at the Sultan Qaboos University Hospital (SQUH), a tertiary care hospital in Oman. Methods: This retrospective observational study included adult patients (≥18 years) who received at least one dose of antiarrhythmic drugs at SQUH between January 2020 and December 2021. Ethical approval was obtained prior to conducting the study. Results: In total, 400 patients were enrolled in this study. Their mean age was 62.5 ± 16.6 years (range:19-96), and 55.3% (221/400) were male. Atrial arrhythmias were the most commonly observed (344/400, 86.0%). Beta-blockers (337/500, 67.4%) were the most prescribed class of drugs. The most commonly prescribed drugs were bisoprolol (263/400, 65.8%), carvedilol (65/400, 16.3%), and amiodarone (59/400, 14.8%). The majority of patients (300/400, 75.0%) received monotherapy, whereas 25% (100/400) received combination therapy. A total of 109 side effects were reported in 45 patients, resulting in an incidence rate of 11.3 %, with cardiovascular side effects accounting for the majority (41/109, 37.6%) of these. Amiodarone had the highest prevalence of adverse effects (33/109, 30.3%). A total of 122 clinical pharmacist interventions were observed in 13.0 % (52/400) of patients. Beta-blockers were associated with more than half of the interventions (61/122, 50.0%). Age (61.84 years vs. 66.75 years; p=0.047), comorbidities (83.6% vs. 96.2%; p=0.019), renal impairment (19.6% vs. 40.4%; p=0.001, heart failure (11.8% vs. 28.9%; p=0.002), concomitant medications (84.5% vs. 98.1%; p=0.004), polypharmacy (51.1% vs. 69.2%; p=0.022) and duration of therapy of less than one year (9.3% vs. 27.3%; p<0.001) was significantly associated with the need for intervention. Conclusion: Beta-blockers were the most commonly prescribed antiarrhythmic drugs in SQUH. Amiodarone was associated with the highest prevalence of side effects. Clinical pharmacy intervention at the SQUH was mainly related to antiarrhythmic drug selection and dose optimization.","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"15 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79235092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.18549/pharmpract.2023.2.2807
Prasojo Pribadi, S. A. Kristina, M. Farrukh
Background: Mental health literacy is necessary for early recognition and intervention of mental disorders. Its multifaceted structure provides useful perspectives for developing a tool to assess mental health literacy. Objective: This study aimed to adapt the Mental Health Literacy Questionnaire (MHLq) designed to observe mental health literacy among university students and to test its construct validity and internal consistency. The impact of a sociodemographic variable on mental health literacy score was also explored. Methods: A number of 650 university students participated in this study. The questionnaire items were adapted using a backward forward translation. An exploratory factor analysis was conducted to examine the construct validity. Internal consistency of the questionnaire was tested using Cronbach’s Alpha. Results: The results showed that the MHLq modified version possessed good validity and reliability (total scale α=0.821) that may be used as a screening tool by mental health professionals and researchers to identify intervention needs among university students. Conclusions: This study also found that individuals who identified knowing someone with a mental health problem performed better on the MHLq global score and three-dimensional factors than those who did not. Future studies are needed to further develop and adapt the questionnaire to reach different target-populations.
{"title":"Psychometric properties of a mental health literacy questionnaire for university students in Indonesia","authors":"Prasojo Pribadi, S. A. Kristina, M. Farrukh","doi":"10.18549/pharmpract.2023.2.2807","DOIUrl":"https://doi.org/10.18549/pharmpract.2023.2.2807","url":null,"abstract":"Background: Mental health literacy is necessary for early recognition and intervention of mental disorders. Its multifaceted structure provides useful perspectives for developing a tool to assess mental health literacy. Objective: This study aimed to adapt the Mental Health Literacy Questionnaire (MHLq) designed to observe mental health literacy among university students and to test its construct validity and internal consistency. The impact of a sociodemographic variable on mental health literacy score was also explored. Methods: A number of 650 university students participated in this study. The questionnaire items were adapted using a backward forward translation. An exploratory factor analysis was conducted to examine the construct validity. Internal consistency of the questionnaire was tested using Cronbach’s Alpha. Results: The results showed that the MHLq modified version possessed good validity and reliability (total scale α=0.821) that may be used as a screening tool by mental health professionals and researchers to identify intervention needs among university students. Conclusions: This study also found that individuals who identified knowing someone with a mental health problem performed better on the MHLq global score and three-dimensional factors than those who did not. Future studies are needed to further develop and adapt the questionnaire to reach different target-populations.","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"70 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72660819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.18549/pharmpract.2023.2.2821
Marnix P D Westein, A. Koster, S. V. D. van der Burgt, M. Bouvy, R. Kusurkar
Background: Quality of the educational environment affects trainee performance and well-being in postgraduate healthcare education. In pharmacy practice the quality of the educational environment has not been extensively studied. Self-determination Theory can assist in understanding the underlying mechanisms. Objectives: In this study, the quality of the educational environment and its relationship with satisfaction and frustration of trainees’ basic psychological needs and motivation were investigated in a Dutch community pharmacy postgraduate education programme. Methods: In a cross-sectional study, pharmacists specializing to become community pharmacists completed the Scan of Postgraduate Educational Environment Domains (SPEED), the Basic Psychological Need Satisfaction and Frustration Scale for the Work Domain, and the Academic Motivation Scale. Confirmatory factor analysis followed by path analysis was used to analyse the relationships between the variables. Results: Out of 232 trainees, 205 responded (88%). Most trainees (82%) were positive about the quality of the educational environment. The resulting path model displayed a moderate to good fit. The perceived quality of the educational environment had a moderate positive association with basic psychological needs satisfaction (Factor loading = 0.40) and a similar negative association with basic psychological needs frustration (Factor loading = -0.47). Basic psychological needs frustration had a moderate association with an increased sense of internal and external pressures also known as controlled motivation (Factor loading = 0.31). Intrinsic motivation was not affected by the perceived quality of the educational environment. Conclusions: The educational environment was perceived as positive in most community pharmacies. However, having a less positive or a negative perception was associated with reduced satisfaction and increased frustration of trainees’ basic needs for autonomy, compentence and relatedness. Moreover, basic psychological needs frustration was associated with an increased perception of controlled motivation. We recommend supporting supervisors in creating a positive educational environment in pharmacy practice, thereby reducing the risk of basic psychological needs frustration and increased controlled motivation amongst trainees.
{"title":"Quality of the educational environment in postgraduate community pharmacy education and the relationship with trainees’ basic psychological needs","authors":"Marnix P D Westein, A. Koster, S. V. D. van der Burgt, M. Bouvy, R. Kusurkar","doi":"10.18549/pharmpract.2023.2.2821","DOIUrl":"https://doi.org/10.18549/pharmpract.2023.2.2821","url":null,"abstract":"Background: Quality of the educational environment affects trainee performance and well-being in postgraduate healthcare education. In pharmacy practice the quality of the educational environment has not been extensively studied. Self-determination Theory can assist in understanding the underlying mechanisms. Objectives: In this study, the quality of the educational environment and its relationship with satisfaction and frustration of trainees’ basic psychological needs and motivation were investigated in a Dutch community pharmacy postgraduate education programme. Methods: In a cross-sectional study, pharmacists specializing to become community pharmacists completed the Scan of Postgraduate Educational Environment Domains (SPEED), the Basic Psychological Need Satisfaction and Frustration Scale for the Work Domain, and the Academic Motivation Scale. Confirmatory factor analysis followed by path analysis was used to analyse the relationships between the variables. Results: Out of 232 trainees, 205 responded (88%). Most trainees (82%) were positive about the quality of the educational environment. The resulting path model displayed a moderate to good fit. The perceived quality of the educational environment had a moderate positive association with basic psychological needs satisfaction (Factor loading = 0.40) and a similar negative association with basic psychological needs frustration (Factor loading = -0.47). Basic psychological needs frustration had a moderate association with an increased sense of internal and external pressures also known as controlled motivation (Factor loading = 0.31). Intrinsic motivation was not affected by the perceived quality of the educational environment. Conclusions: The educational environment was perceived as positive in most community pharmacies. However, having a less positive or a negative perception was associated with reduced satisfaction and increased frustration of trainees’ basic needs for autonomy, compentence and relatedness. Moreover, basic psychological needs frustration was associated with an increased perception of controlled motivation. We recommend supporting supervisors in creating a positive educational environment in pharmacy practice, thereby reducing the risk of basic psychological needs frustration and increased controlled motivation amongst trainees.","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"35 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78075975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.18549/pharmpract.2023.2.2724
Chu Hc, Chan Yl, Liou Jh, Chen Hm
Background: The COVID-19 pandemic has created dramatic challenges for healthcare systems around the world, including Taiwan. At the end of January 2022, there were 17,951 confirmed cases and 851 deaths nationwide, while the COVID-19 vaccination coverage rate in Taiwan was only 80.8%, making it hard to defend against the quick mutation of the virus, which gave rise to variants, such as Omicron. Objective(s): To safeguard the rights of patients to receive medicines in a safe way, we offered three new pharmaceutical services, including an outdoor medicine dispensing refillable prescription service, telemedicine, and a queue management system. The purpose of this article is to share our successful experience and to investigate the impact of outdoor pharmaceutical services during the COVID-19 pandemic. Methods: In order to provide patients with an outdoor medicine dispensing refillable prescription service and telemedicine service, prior arrangement through a booking system was required. Patients could obtain a queue ticket through a multi-media intelligent serving machine or the counter. We also relocated one of our counters from the pharmacy department to the front lobby during the morning peak hours. Then we gave surveys via paper questionnaires in 2020 and Google Forms in 2021 to confirm that the services were helpful. Results: A total of 24,248 person-times were recorded for chronic disease patients with refillable prescriptions visiting our hospital in 2020, compared with 14,134 person-times in 2021. For the queue management system, the total number of person-times in 2020 was 26,670, which relieved about a quarter of the waiting outpatient burden. Furthermore, use of telemedicine totaled 3,369 person-times. A high proportion (over 90%) of patients reported being satisfied with these services. Conclusions: The three new pharmaceutical services not only prevented patients from interrupting their medications during the epidemic period, but also reduced the risk of contagion. All three services provided outpatients with a safe and low-risk method of picking up their medications, and a high proportion of patients were satisfied with these services
{"title":"A strategy of providing outdoor medicine dispensing services for outpatients during the COVID-19 pandemic.","authors":"Chu Hc, Chan Yl, Liou Jh, Chen Hm","doi":"10.18549/pharmpract.2023.2.2724","DOIUrl":"https://doi.org/10.18549/pharmpract.2023.2.2724","url":null,"abstract":"Background: The COVID-19 pandemic has created dramatic challenges for healthcare systems around the world, including Taiwan. At the end of January 2022, there were 17,951 confirmed cases and 851 deaths nationwide, while the COVID-19 vaccination coverage rate in Taiwan was only 80.8%, making it hard to defend against the quick mutation of the virus, which gave rise to variants, such as Omicron. Objective(s): To safeguard the rights of patients to receive medicines in a safe way, we offered three new pharmaceutical services, including an outdoor medicine dispensing refillable prescription service, telemedicine, and a queue management system. The purpose of this article is to share our successful experience and to investigate the impact of outdoor pharmaceutical services during the COVID-19 pandemic. Methods: In order to provide patients with an outdoor medicine dispensing refillable prescription service and telemedicine service, prior arrangement through a booking system was required. Patients could obtain a queue ticket through a multi-media intelligent serving machine or the counter. We also relocated one of our counters from the pharmacy department to the front lobby during the morning peak hours. Then we gave surveys via paper questionnaires in 2020 and Google Forms in 2021 to confirm that the services were helpful. Results: A total of 24,248 person-times were recorded for chronic disease patients with refillable prescriptions visiting our hospital in 2020, compared with 14,134 person-times in 2021. For the queue management system, the total number of person-times in 2020 was 26,670, which relieved about a quarter of the waiting outpatient burden. Furthermore, use of telemedicine totaled 3,369 person-times. A high proportion (over 90%) of patients reported being satisfied with these services. Conclusions: The three new pharmaceutical services not only prevented patients from interrupting their medications during the epidemic period, but also reduced the risk of contagion. All three services provided outpatients with a safe and low-risk method of picking up their medications, and a high proportion of patients were satisfied with these services","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"14 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82506596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.18549/pharmpract.2023.2.2808
Yusransyah Yusransyah, S. A. Kristina, D. Endarti
Background: The development of several HPV-related control techniques for the prevention of cervical cancer followed the identification of a link between high-risk human papillomavirus (HPV) infection and the occurrence of cervical cancer. Objective: The objective of the current study was to determine how cost-effective the different cervical cancer screening programs and HPV vaccinations in Indonesia. Methods: The lifetime costs and effects of vaccination among adolescent girls or screening with either the VIA, Papanicolaou, or HPV DNA test at various time intervals in a hypothetical cohort of 30-65 years-old women were estimated using a Markov model based on a societal perspective. Results: Based on statistics on transition probabilities, efficacy of HPV vaccination, and diagnostic accuracy of screening procedures. The findings of this study, specifically the cost-effectiveness of preventing cervical cancer with vaccination, revealed that each woman’s vaccination cost was $16. The amount of disease-adjusted life years (DALYs) that may be saved was $213, and the averted cost per death was $1.438. Conclusion: Early cervical cancer screening using the IVA test method has a net cost of $576 for years of quality-adjusted life saved and costs $18 each examination for each woman, $1,532 for each preventable death. When the group of teenage girls who received the HPV, vaccine reaches the age of 30, the VIA screening frequency should be decided depending on the cohort’s overall HPV vaccination coverage.
{"title":"Cost effectiveness of cervical cancer prevention strategies in Indonesia","authors":"Yusransyah Yusransyah, S. A. Kristina, D. Endarti","doi":"10.18549/pharmpract.2023.2.2808","DOIUrl":"https://doi.org/10.18549/pharmpract.2023.2.2808","url":null,"abstract":"Background: The development of several HPV-related control techniques for the prevention of cervical cancer followed the identification of a link between high-risk human papillomavirus (HPV) infection and the occurrence of cervical cancer. Objective: The objective of the current study was to determine how cost-effective the different cervical cancer screening programs and HPV vaccinations in Indonesia. Methods: The lifetime costs and effects of vaccination among adolescent girls or screening with either the VIA, Papanicolaou, or HPV DNA test at various time intervals in a hypothetical cohort of 30-65 years-old women were estimated using a Markov model based on a societal perspective. Results: Based on statistics on transition probabilities, efficacy of HPV vaccination, and diagnostic accuracy of screening procedures. The findings of this study, specifically the cost-effectiveness of preventing cervical cancer with vaccination, revealed that each woman’s vaccination cost was $16. The amount of disease-adjusted life years (DALYs) that may be saved was $213, and the averted cost per death was $1.438. Conclusion: Early cervical cancer screening using the IVA test method has a net cost of $576 for years of quality-adjusted life saved and costs $18 each examination for each woman, $1,532 for each preventable death. When the group of teenage girls who received the HPV, vaccine reaches the age of 30, the VIA screening frequency should be decided depending on the cohort’s overall HPV vaccination coverage.","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"42 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88703811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.18549/pharmpract.2023.2.2743
Shatha M. Al Omari, Hamza Alhamad, M. Barakat, Hana M Sawan, Marcia C Mecca, F. Al Bahar
Objective: Pharmacists are in a unique position to identify medications that should be deprescribed. Including deprescribing as part of medical and pharmacy curriculum has been proposed as a substantial change to increase the practice of deprescribing. The aims of this study were to evaluate if pharmacy students were exposed to the term of deprescribing in their classes and how they were taught about it (e.g., lecture, case problems, experiential). We also aimed to assess the deprescribing knowledge, attitudes, abilities, and confidence of pharmacy students in Jordan. Methods: Both paper-based and online questionnaires surveys were distributed to third year pharmacy students and above at 12 schools of pharmacy in addition to graduated student (bachelors and diploma). The survey included three sections, including (i) demographics and questions on their exposure to deprescribing and other experiences within their curriculum; (ii) questions regarding their attitudes, ability, and confidence regarding deprescribing, and (iii) questions to assess the factors that may influence the deprescribing process from the students’ perspectives. Study responses were extracted from Google Form® as an Excel sheet and exported into Statistical Package for Social Sciences version 24.0 (SPSS Inc., Armonk, NY: IBM Corp, USA) for statistical analyses. Descriptive statistics, including frequency and proportions, were calculated and reported appropriately. Results: Around half of the participating students (n=202, 49.5%) were familiar with the term “Deprescribing,” and only 74 (18.1%) students reported exposure to deprescribing instruction through required coursework. Less than half (n=193, 47.3%) reported exposure during elective courses, and fewer (n=47, 11.5%) reported exposure in both required and elective courses. Less than half of the students (n=191, 46.8%) were confident to recommend deprescribing strategies for health care providers in patients with potentially inappropriate medications. Conclusion: The results of this study revealed that pharmacy students’ attitudes and perceptions about deprescribing were generally positive, however, for didactic and experiential training, pharmacy schools should assess their curricula and consider adding content and assessment of deprescribing knowledge and skills.
目的:药剂师在确定应该开处方的药物方面处于独特的地位。建议将开处方作为医学和药学课程的一部分，这是增加开处方做法的一个重大变化。本研究的目的是评估药剂学学生是否在课堂上接触到处方描述这个术语，以及他们是如何被教导的(例如，讲座，案例问题，经验)。我们还旨在评估约旦药学专业学生的处方知识、态度、能力和信心。方法:对12所药学院药学三年级及以上学生进行问卷调查，并对本科及大专毕业生进行问卷调查。调查包括三个部分，包括(i)人口统计数据以及他们在课程中接触处方和其他经验的问题;(ii)关于他们对处方的态度、能力和信心的问题，(iii)从学生的角度评估可能影响处方过程的因素的问题。研究结果从b谷歌Form®中提取为Excel表格，并导出到Statistical Package for Social Sciences version 24.0 (SPSS Inc.， Armonk, NY: IBM Corp, USA)进行统计分析。描述性统计，包括频率和比例，被适当地计算和报告。结果:大约一半的参与学生(n=202, 49.5%)熟悉术语“处方化”，只有74名(18.1%)学生报告通过必修课程接触到处方化教学。不到一半(n=193, 47.3%)报告在选修课程中暴露，较少(n=47, 11.5%)报告在必修课和选修课程中都暴露。不到一半的学生(n=191, 46.8%)有信心向医疗保健提供者推荐可能不适当药物的处方策略。结论:本研究结果显示，药学院学生对处方解除的态度和看法总体上是积极的，但对于教学和体验式培训，药学院应对其课程进行评估，并考虑增加处方解除知识和技能的内容和评估。
{"title":"Attitudes and perceptions of Jordanian pharmacy students toward deprescribing: a cross-sectional study","authors":"Shatha M. Al Omari, Hamza Alhamad, M. Barakat, Hana M Sawan, Marcia C Mecca, F. Al Bahar","doi":"10.18549/pharmpract.2023.2.2743","DOIUrl":"https://doi.org/10.18549/pharmpract.2023.2.2743","url":null,"abstract":"Objective: Pharmacists are in a unique position to identify medications that should be deprescribed. Including deprescribing as part of medical and pharmacy curriculum has been proposed as a substantial change to increase the practice of deprescribing. The aims of this study were to evaluate if pharmacy students were exposed to the term of deprescribing in their classes and how they were taught about it (e.g., lecture, case problems, experiential). We also aimed to assess the deprescribing knowledge, attitudes, abilities, and confidence of pharmacy students in Jordan. Methods: Both paper-based and online questionnaires surveys were distributed to third year pharmacy students and above at 12 schools of pharmacy in addition to graduated student (bachelors and diploma). The survey included three sections, including (i) demographics and questions on their exposure to deprescribing and other experiences within their curriculum; (ii) questions regarding their attitudes, ability, and confidence regarding deprescribing, and (iii) questions to assess the factors that may influence the deprescribing process from the students’ perspectives. Study responses were extracted from Google Form® as an Excel sheet and exported into Statistical Package for Social Sciences version 24.0 (SPSS Inc., Armonk, NY: IBM Corp, USA) for statistical analyses. Descriptive statistics, including frequency and proportions, were calculated and reported appropriately. Results: Around half of the participating students (n=202, 49.5%) were familiar with the term “Deprescribing,” and only 74 (18.1%) students reported exposure to deprescribing instruction through required coursework. Less than half (n=193, 47.3%) reported exposure during elective courses, and fewer (n=47, 11.5%) reported exposure in both required and elective courses. Less than half of the students (n=191, 46.8%) were confident to recommend deprescribing strategies for health care providers in patients with potentially inappropriate medications. Conclusion: The results of this study revealed that pharmacy students’ attitudes and perceptions about deprescribing were generally positive, however, for didactic and experiential training, pharmacy schools should assess their curricula and consider adding content and assessment of deprescribing knowledge and skills.","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"23 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83227217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：